康希諾生物(06185.HK)發佈年度業績 研發開支增加33.5%至1.517億元
格隆匯3月27日丨康希諾生物-B(06185.HK)發佈年度業績,截至2019年12月31日止年度,公司並無產生任何收入。2018年度,公司向獨立第三方提供研發服務,以通過公司先進的疫苗研發平台技術篩選及驗證若干抗體,因而錄得收入人民幣110萬元。
研發開支方面,公司的研發開支由2018年度的人民幣1.136億元增加33.5%至2019年度的人民幣1.517億元,主要由於(i)僱員福利開支增加人民幣2700萬元;及(ii)折舊及攤銷增加人民幣750萬元。
公司表示,康希諾的使命是研發、生產和商業化高質量、創新及經濟實惠的疫苗。肩負此使命的,是公司傑出的創始人和高級管理層團隊,包括多位擁有於全球製藥公司領導創新國際疫苗研發經驗的世界頂尖科學家。其他管理層成員均來自領先的跨國及國內生物製藥公司,亦為疫苗行業的資深人士。
公司的疫苗產品線在戰略上旨在針對中國龐大且供不應求的市場,可總結為三個類別:(i)全球創新疫苗(如Ad5-EBOV、公司的在研結核病加強疫苗、在研PBPV 及在研Ad5-nCoV),以迎合中國尚未滿足的醫療需求;(ii)研發潛在的中國首創疫苗,憑藉質量更高的世界級疫苗取代現時的主流疫苗(如公司的在研DTcP疫苗及在研MCV4);及(iii)研發出與中國市場的進口產品競爭的中國潛在最佳疫苗(如公司的在研PCV13i)。
此外,公司正為13個疾病領域研發16種在研疫苗。除了公司預防腦膜炎球菌感染及埃博拉病毒疫病的三項臨近商業化疫苗產品之外,公司有7種在研疫苗處於臨牀試驗階段或臨牀試驗申請階段。公司亦有6種臨牀前在研疫苗,包括一種在研聯合疫苗。迄今為止,公司尚未將任何產品商業化,公司亦無法保證公司將能夠成功研發及商業化公司的在研疫苗。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.